Selroos O, Halme M
Mjölbolsta Hospital, Finland.
Thorax. 1991 Dec;46(12):891-4. doi: 10.1136/thx.46.12.891.
High doses of inhaled corticosteroids are absorbed systemically and may cause long term side effects. As rinsing the mouth out after use and inhaling through a spacing device may reduce systemic absorption this has been further investigated.
Three crossover studies were carried out to assess the effect of budesonide given by dry powder inhaler (Turbuhaler) with and without mouth rinsing and beclomethasone dipropionate given by metered dose inhaler with or without a spacing device (Volumatic) on serum cortisol concentrations and urinary cortisol excretion in patients with asthma taking an inhaled corticosteroid. Each treatment period was two weeks with in a two week washout period. Serum cortisol concentrations at 0800 hours on day 14 and the 24 hour urinary excretion of cortisol were measured. In study 1 24 patients taking beclomethasone dipropionate 500 micrograms twice a day inhaled with (n = 10) or without (n = 14) a Volumatic spacing device were switched to a budesonide dry powder inhaler, 600 micrograms to be taken twice a day without mouth rinsing. In study 2 10 patients took budesonide 800 micrograms twice a day with and without mouth rinsing and without swallowing the rinsing water. In study 3 17 patients took budesonide 800 micrograms twice daily with mouth rinsing and beclomethasone dipropionate 500 micrograms twice daily with the spacing device and mouth rinsing.
In study 1 no difference was seen between budesonide without mouth rinsing and beclomethasone dipropionate without a spacer: beclomethasone with spacer caused less suppression of cortisol (mean (SD) serum cortisol concentration: beclomethasone and spacer 487(148), budesonide 368(145) nmol/l). In study 2 mouth rinsing caused less suppression of morning serum cortisol concentrations (rinsing 440(63), no rinsing 375(56) nmol/1). In study 3 there was no difference in serum or urinary cortisol concentrations between twice daily beclomethasone dipropionate 500 micrograms inhaled by Volumatic spacer or budesonide by Turbuhaler 800 micrograms twice daily, both with mouth rinsing. Individual serum cortisol values were within the normal range in all patients except one in study 1.
Systemic absorption of a corticosteroid inhaled from a metered dose inhaler is reduced by using a spacing device and that from a dry powder inhaler by mouth rinsing.
高剂量吸入性糖皮质激素会被全身吸收,可能导致长期副作用。由于使用后漱口以及通过间隔装置吸入可减少全身吸收,对此进行了进一步研究。
开展了三项交叉研究,以评估使用或不使用漱口,通过干粉吸入器(都保)给予布地奈德,以及使用或不使用间隔装置(储雾罐)通过定量气雾剂给予丙酸倍氯米松,对正在吸入糖皮质激素的哮喘患者血清皮质醇浓度和尿皮质醇排泄的影响。每个治疗期为两周,期间有两周的洗脱期。测量第14天08:00时的血清皮质醇浓度以及皮质醇的24小时尿排泄量。在研究1中,24名每天两次吸入500微克丙酸倍氯米松的患者,分别使用(n = 10)或不使用(n = 14)储雾罐,转而使用布地奈德干粉吸入器,每天两次吸入600微克且不进行漱口。在研究2中,10名患者每天两次吸入800微克布地奈德,分别进行和不进行漱口,且不吞咽漱口水。在研究3中,17名患者每天两次吸入800微克布地奈德并漱口,以及每天两次吸入500微克丙酸倍氯米松并使用间隔装置且漱口。
在研究1中,不进行漱口的布地奈德与不使用间隔装置的丙酸倍氯米松之间未见差异:使用间隔装置的丙酸倍氯米松对皮质醇的抑制作用较小(平均(标准差)血清皮质醇浓度:丙酸倍氯米松与间隔装置487(148),布地奈德368(145)nmol/l)。在研究2中,漱口对早晨血清皮质醇浓度的抑制作用较小(漱口440(63),不漱口375(56)nmol/l)。在研究3中,通过储雾罐每天两次吸入500微克丙酸倍氯米松或通过都保每天两次吸入800微克布地奈德,两者均进行漱口,血清或尿皮质醇浓度无差异。除研究1中的一名患者外,所有患者的个体血清皮质醇值均在正常范围内。
使用间隔装置可减少从定量气雾剂吸入的糖皮质激素的全身吸收,而漱口可减少从干粉吸入器吸入的糖皮质激素的全身吸收。